Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against ‘Meningitis B’ could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom. Teenagers at participating schools are being asked to take part by local research teams involved.

Meningitis is caused by an infection around the surface of the brain. It is rare but can be life-threatening and mostly affects babies, young children and adolescents. An important cause of meningitis is a type of bacteria (or germs) called meningococcus.

For more information, please visit  http://beontheteam.uk/ or http://trials.ovg.ox.ac.uk/trials/be-on-the-team

What is the ‘Be on the TEAM’ study?

  • This study will see if immunising teenagers with MenB vaccines reduces the carriage of meningococcus in teenager’s throats, which could in turn protect the broader community
  • Teenagers who take part will receive 2 doses of a Meningitis B vaccine
  • These are licensed vaccines that teenagers would not otherwise receive, and will reduce their risk of meningitis
  • Participants would have two throat swabs taken 1 year apart
  • There would be three study visits, over 12 to 18 months
  • All visits would be held within participating schools

Which schools are taking part?

The schools listed below are participating within the Thames Valley

    • Cheney School, Oxford
    • The Grange School, Aylesbury
    • Kennet School, Thatcham
    • King Alfred’s Academy, Wantage
    • Matthew Arnold School, Oxford
    • Our Lady’s School, Abingdon
    • Queen Anne’s School, Caversham
    • Tudor Hall School, Banbury
    • Park House School, Newbury
    • Radley College, Abingdon
    • Magdalen College School, Oxford
    • St Bartholomew's School, Newbury
    • Oxford High School, Oxford
    • Headington School, Oxford

    Where can I find out more information?

    The Oxford Vaccine Group study information booklets contain more information (Information booklet)

    If you would like any further information regarding the study please contact the study team on:

    Email: mencarriage@ovg.ox.ac.uk

    Tel: 01865611400

    Many thanks,

    The MenB Carriage Team

    Oxford Vaccine Group

     

    Similar stories

    Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

    A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

    Kintampo Health Research Centre Begin Clinical Trial of Lassa Fever Vaccine in Ghana

    The Kintampo Health Research Centre (KHRC) has begun a clinical trial to test a new vaccine candidate against Lassa fever. This is an early-stage (Phase 1b) trial which will primarily assess the safety of the ChAdOx1 LassaJ vaccine and how the immune system responds to it.

    Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

    Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

    First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

    Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

    BD-Ebov trial advances following completion of sentinel vaccinations

    The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

    World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

    Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

    Similar stories

    Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

    A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

    Kintampo Health Research Centre Begin Clinical Trial of Lassa Fever Vaccine in Ghana

    The Kintampo Health Research Centre (KHRC) has begun a clinical trial to test a new vaccine candidate against Lassa fever. This is an early-stage (Phase 1b) trial which will primarily assess the safety of the ChAdOx1 LassaJ vaccine and how the immune system responds to it.

    Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

    Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

    First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

    Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

    BD-Ebov trial advances following completion of sentinel vaccinations

    The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

    World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

    Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.